Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 07, 2024 10:00 ET | Source: Liquidia Corporation

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent

U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any...
October 02, 2024 06:00 ET | Source: Liquidia Corporation

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.
September 30, 2024 08:00 ET | Source: Liquidia Corporation

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Liquidia will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians this October.
September 16, 2024 09:41 ET | Source: Liquidia Corporation

Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare...
September 11, 2024 08:26 ET | Source: Liquidia Corporation

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

Liquidia Corporation announces raise of $67.5M.
August 28, 2024 08:00 ET | Source: Liquidia Corporation

Liquidia to Present at Upcoming Investor Conferences

Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.
August 22, 2024 06:00 ET | Source: Liquidia Corporation

Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD

Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.
August 19, 2024 06:00 ET | Source: Liquidia Corporation

U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.
August 16, 2024 06:30 ET | Source: Liquidia Corporation

Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions

Liquidia Corporation (NASDAQ: LQDA) will present nine encore thematic posters at the 2024 Pulmonary Hypertension Association (PHA) International Conference
August 07, 2024 06:30 ET | Source: Liquidia Corporation

Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.